Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ibuprofen + isosorbide dinitrate
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), and isosorbide dinitrate, a nitric oxide donor. This combination has been studied for the treatment of muscular dystrophies, particularly Duchenne muscular dystrophy. The combination works through complementary mechanisms where isosorbide dinitrate promotes vasodilation and improves blood flow while ibuprofen provides anti-inflammatory effects.
- Other names
- ibuprofen and isosorbide dinitrate combination
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)sGC (Soluble Guanylyl Cyclase)
Beyond the preview
Go deeper on ibuprofen + isosorbide dinitrate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ibuprofen + isosorbide dinitrate.